1. Novartis AG (NYSE:NVS)
Short Percentage of Shares Outstanding: 0.24%
On June 12, Novartis AG (NYSE:NVS) presented results from the RemIND trial at the European Academy of Allergy and Clinical Immunology Congress, demonstrating that Rhapsido achieved its primary endpoints across the three most common chronic inducible urticaria subtypes. The therapy became the first treatment to show efficacy in a global Phase III clinical trial for chronic inducible urticaria, with higher rates of complete responses observed by week 12 and clinical benefits emerging as early as week 2 in two of the subtypes. The findings suggest that Rhapsido may offer durable symptom relief for patients whose condition remains inadequately controlled despite treatment with second-generation H1-antihistamines.
On June 10, Novartis AG (NYSE:NVS) announced a multi-year collaboration with Orionis Biosciences to discover and develop molecular glue therapeutics targeting challenging disease pathways across multiple therapeutic areas. The agreement expands the companies’ existing relationship and will combine Orionis’ Allo-Glue platform and AI-driven discovery capabilities with Novartis’ drug development expertise to accelerate target identification, ligase profiling, and molecular glue optimization. Under the terms of the collaboration, Orionis will receive a $40 million upfront payment and may earn up to $1.4 billion in research, development, and commercial milestone payments, in addition to tiered royalties on future product sales.
Incorporated in March 1996 and headquartered in Basel, Switzerland, Novartis AG (NYSE:NVS) is a multinational pharmaceutical corporation that researches and develops innovative prescription medicines. The company explores the mTOR pathway via the rapamycin (sirolimus) class of compounds, aiming to delay age-related diseases and extend health span.
While we acknowledge the potential of NVS as a longevity and anti-aging stock, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVS and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Under-the-Radar AI Stocks to Buy in 2026 and Top 10 Stocks That Members of Congress Own.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
